eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its u.s. subsidiary eisai inc. has entered into a memorandum of understanding with c2n diagnostics (“c2n”) that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including alzheimer’s disease (ad), may help patients receive a timely diagnosis and appropriate treatment. collaborating with c2n, eisai inc. will work to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment in clinical practice outside of clinical trial settings in the u.s. blood-based assays could result in the development of new standards in clinical care that may enable timely and accurate diagnoses for people living with cognitive impairment.
爱游戏app官网登录入口 copyright(c) 2011 eisai china lnc.all rights reserved.
customer service hotline
021-62881220